Last reviewed · How we verify
MAP0010 high dose
At a glance
| Generic name | MAP0010 high dose |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Blood Level Study of Unit Dose Budesonide (PHASE1)
- A Study of 2 Doses of MAP0010 in Adult Asthmatics (PHASE2)
- Study of MAP0010 in Asthmatic Children and Adolescents (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAP0010 high dose CI brief — competitive landscape report
- MAP0010 high dose updates RSS · CI watch RSS
- Allergan portfolio CI